Microtechnologies For Immune Health Profiling In Type 2 Diabetes Mellitus

Friday, 15 November 2019 at 15:00

Add to Calendar ▼2019-11-15 15:00:002019-11-15 16:00:00Europe/LondonMicrotechnologies For Immune Health Profiling In Type 2 Diabetes MellitusMicrofluidics and Organ-on-a-Chip Asia 2019 in Tokyo, JapanTokyo, JapanSELECTBIOenquiries@selectbiosciences.com

Metabolic disorders such as diabetes mellitus and cardiovascular diseases (CVD) are becoming the main public health challenges in Singapore and globally with rising premature morbidity and associated mortality, as well as escalating healthcare costs. In this talk, I will present our recent research efforts in the development of microfluidics technologies for “label-free” isolation and phenotyping of circulating leukocytes in type 2 DM (T2DM). We demonstrated that diabetic leukocytes exhibited significant immune dysfunctions which were well-associated with traditional CVD risk factors, clearly illustrating their potential as novel surrogate biomarkers for point-of-care testing. Overall, this multi-disciplinary research greatly facilitates rapid and quantitative analysis of immune and vascular health using liquid biopsy, with progress towards clinical diagnostics and precision medicine in the treatment of vascular dysfunctions.

Han Wei Hou, Assistant Professor, School of Mechanical and Aerospace Engineering, Nanyang Technological University

Han Wei Hou

Dr. Han Wei Hou is currently an Assistant Professor at the School of Mechanical and Aerospace Engineering, and the Lee Kong Chian School of Medicine (LKCMedicine) at Nanyang Technological University (NTU), Singapore. He received his BEng (First Class Hons) and PhD degree in Biomedical Engineering at the National University of Singapore in 2008 and 2012, respectively. Upon graduation, he did his postdoctoral training at Massachusetts Institute of Technology, and subsequently joined LKCMedicine at NTU as the inaugural LKCMedicine Postdoctoral Fellow in 2014. His research focus on developing novel microfluidics point-of-care testing, and biomimetic organ-on-chip technologies for translational diabetes and cardiovascular diseases research. (Research group website: www.hwhoulab.com)